4.8 Article

Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota

Journal

NATURE MEDICINE
Volume 26, Issue 4, Pages 608-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41591-020-0764-0

Keywords

-

Funding

  1. University of Michigan Center for Gastrointestinal Research [DK034933]
  2. Michigan Regional Comprehensive Metabolomics Resource Core (MRC2) [DK097153]
  3. National Institutes of Health (NIH) [DK110146, DK108901]
  4. Crohn's and Colitis Foundation of America
  5. Global Probiotics Council
  6. Joint Usage/Research Program of Medical Mycology Research Center Chiba University 18-1
  7. Japan Society for the Promotion of Science
  8. Uehara Memorial Foundation
  9. Clinical and Translational Science Awards Program
  10. Prevent Cancer Foundation
  11. Japan Society for the Promotion of Science KAKENHI grants [16H04901, 17H05654, 18H04805]
  12. Japan Science and Technology Agency PRESTO grant [JPMJPR1537]
  13. Japan Science and Technology Agency ERATO grant [JPMJER1902]
  14. Advanced Research and Development Programs for Medical Innovation CREST program grant [JP19gm1010009]
  15. Takeda Science Foundation
  16. Food Science Institute Foundation
  17. Swedish Research Council
  18. Grants-in-Aid for Scientific Research [16H04901, 18H04805, 17H05654] Funding Source: KAKEN

Ask authors/readers for more resources

In germ-free mice colonized with human microbiota, mucosal IL-22 signaling promotes the growth of succinate-consuming commensal bacteria via host mucus glycosylation, and transplantation of these bacteria limits Clostridioides difficile infection. The involvement of host immunity in the gut microbiota-mediated colonization resistance to Clostridioides difficile infection (CDI) is incompletely understood. Here, we show that interleukin (IL)-22, induced by colonization of the gut microbiota, is crucial for the prevention of CDI in human microbiota-associated (HMA) mice. IL-22 signaling in HMA mice regulated host glycosylation, which enabled the growth of succinate-consuming bacteria Phascolarctobacterium spp. within the gut microbiome. Phascolarctobacterium reduced the availability of luminal succinate, a crucial metabolite for the growth of C. difficile, and therefore prevented the growth of C. difficile. IL-22-mediated host N-glycosylation is likely impaired in patients with ulcerative colitis (UC) and renders UC-HMA mice more susceptible to CDI. Transplantation of healthy human-derived microbiota or Phascolarctobacterium reduced luminal succinate levels and restored colonization resistance in UC-HMA mice. IL-22-mediated host glycosylation thus fosters the growth of commensal bacteria that compete with C. difficile for the nutritional niche.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available